

Drug Utilization Review Board (DURB) Agenda

April 22, 2022 - 9:00 am

Texas Health and Human Services Commission (HHSC), John H. Winters Building, Public Hearing Room 125, 1st Floor
701 W. 51st Street, Austin, TX
78751

[Webcasting Available \[/about/meetings\]](#)

This meeting will be webcast. Members of the public may attend the meeting in person at the address above or access a live stream of the meeting at [https://texashhsmeetings.org/HHSWebcast \[/node/73176\]](https://texashhsmeetings.org/HHSWebcast[/node/73176]) . Select the tab for the Winters Public Hearing Room Live on the date and time for this meeting. Please e-mail Webcasting@hhsc.state.tx.us [\[mailto:Webcasting@hhsc.state.tx.us\]](mailto:Webcasting@hhsc.state.tx.us) if you have any problems with the webcasting function.

This meeting will also be conducted via videoconference call in accordance with the requirements of Section 551.127, Government Code. The member of the Board presiding over the meeting will be physically present at the location specified above.

Attendees who would like to provide public comment should see the **Public Comment** section below.

1. Call to order and roll call
2. Consideration of January 21, 2022, draft meeting minutes
3. [Open Meetings Act - refresher training for the board](#)
[\[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item3.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item3.pdf)
4. [Consideration of DURB Bylaws revision](#) [\[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item4.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item4.pdf)
5. Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL):
 - a. [Analgesics, narcotics long-acting](#) [\[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5a.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5a.pdf)
 - b. [Anti-Allergens, oral](#) [\[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5b.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5b.pdf)
 - c. [Antibiotics, inhaled](#) [\[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5c.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5c.pdf)
 - d. [Anticoagulants](#) [\[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5d.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5d.pdf)
 - e. [Antidepressants, other](#) [\[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5e.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5e.pdf)
 - f. [Antidepressants, selective serotonin reuptake inhibitors \(SSRIs\)](#)
[\[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5f.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5f.pdf)
 - g. [Antidepressants, tricyclic](#) [\[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5g.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5g.pdf)
 - h. [Antihyperuricemics](#) [\[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5h.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5h.pdf)
 - i. [Antivirals, oral](#) [\[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5i.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5i.pdf)
 - j. [Anxiolytics](#) [\[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5j.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5j.pdf)
 - k. [Benign prostatic hyperplasia treatments](#) [\[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5k.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5k.pdf)
 - l. [Beta-blockers](#) [\[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5l.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5l.pdf)
 - m. [Bile salts](#) [\[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5m.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5m.pdf)

- n. [Bronchodilators, beta-agonists \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5n.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5n.pdf)
- o. [Chronic obstructive pulmonary disease \(COPD\) agents \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5o.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5o.pdf)
- p. [Cough and cold, cold \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5p.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5p.pdf)
- q. [Cough and cold, narcotic \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5q.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5q.pdf)
- r. [Cough and cold, non-narcotic \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5r.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5r.pdf)
- s. [Erythropoiesis stimulating proteins \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5s.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5s.pdf)
- t. [Glucocorticoids, inhaled \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5t.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5t.pdf)
- u. [Hemophilia treatment \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5u.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5u.pdf)
- v. [Hereditary angioedema \(HAE\) treatments \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5v.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5v.pdf)
- w. [Immune globulins, intravenous \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5w.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5w.pdf)
- x. [Immunomodulators, asthma \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5x.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5x.pdf)
- y. [Lincosamides/oxazolidinones/streptogramins \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5y.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5y.pdf)
- z. [Lipotropics, other \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5z.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5z.pdf)
- aa. [Lipotropics, statins \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5aa.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5aa.pdf)
- bb. [Multiple sclerosis agents \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5bb.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5bb.pdf)
- cc. [Pancreatic enzymes \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5cc.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5cc.pdf)
- dd. [Pediatric vitamin preparations \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5dd.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5dd.pdf)
- ee. [Prenatal vitamins \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5ee.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5ee.pdf)
- ff. [Pulmonary arterial hypertension agents, oral and inhaled \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5ff.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5ff.pdf)
- gg. [Sedative hypnotics \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5gg.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5gg.pdf)
- hh. [Sickle cell anemia treatments \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5hh.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5hh.pdf)
- ii. [Thrombopoiesis stimulating proteins \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5ii.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5ii.pdf)
- jj. [Urea cycle disorder, oral \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5jj.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item5jj.pdf)

6. Public comment on single new drugs to be reviewed for the Medicaid PDL:

- a. [Dhivy tablet \(oral\) / Antiparkinson agents \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item6a.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item6a.pdf)
- b. [Eprontia solution \(oral\) / Anticonvulsants \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item6b.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item6b.pdf)
- c. [Skytrofa cartridge \(subcutaneous\) / Growth hormone \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item6c.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item6c.pdf)
- d. [Adbry \(subcutaneous\) / Immunomodulators, atopic dermatitis \[https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item6d.pdf\]](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item6d.pdf)

- e. [Tyrvaya spray \(nasal\) / Ophthalmics, anti-inflammatory/immunomodulators](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item6e.pdf)
- f. [Vuity \(ophthalmic\) / Ophthalmics, glaucoma agents](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item6f.pdf)

- 7. Therapeutic and clinical drug reviews and updates: Magellan Medicaid Administration
- 8. Executive work session

Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the DURB may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.

- 9. Announcements of drugs recommended for the Medicaid PDL: Magellan Medicaid Administration
- 10. [Retrospective drug utilization review \(DUR\): Conduent, LLC](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item10.pdf)
 - a. Recent interventions
 - i. Hypertension management
 - ii. Attention-deficit/hyperactivity disorder management
 - b. Recent outcome reports
 - i. [Comprehensive opioid management](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item10bi.pdf)
 - ii. [Management of psychotropic drugs in pediatrics](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item10bii.pdf)
 - c. Potential RetroDUR interventions
 - i. [Heart failure management](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item10ci.pdf)
 - ii. [Migraine disease management](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item10cii.pdf)
- 11. [Prospective prior authorization proposals \(clinical edits\): Kepro, LLC](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item11.pdf)
 - a. [Atopic Dermatitis – add Cibinqo \(abrocitinib\) and Adbry\(tralokinumab-ldrm\)](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item11a.pdf)
 - b. [Livmarli \(maralixibat\) – new criteria for cholestatic pruritis due to Alagille syndrome](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item11b.pdf)
 - c. [Recorlev\(levoketoconazole oral tablets\)- new criteria for Cushing Disease](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item11c.pdf)
 - d. [Tyrvaya\(varenicline nasal\) – new criteria for dry eye](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item11d.pdf)
 - e. [Voxzogo \(vosoritide\)- new criteria for achondroplasia](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item11e.pdf)
- 12. [Retrospective drug use criteria for outpatient use in Vendor Drug Program: The University of Texas at Austin College of Pharmacy](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item12.pdf)
 - a. [Benzodiazepines \(non-sedative/hypnotics\)](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item12a.pdf)
 - b. [Complement Inhibitor and Enzyme/ Protein Replacement Therapy](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item12b.pdf)
 - c. [Direct oral anticoagulants](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item12c.pdf)
 - d. [Hydroxy-Methylglutaryl Coenzyme A Reductase Inhibitors](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item12d.pdf)

- e. [Ivacaftor \(Kalydeco\) and Combination Therapy \(Resubmission from the January Meeting\)](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item12e.pdf) [<https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item12e.pdf>]
- f. [Low Molecular-Weight Heparins](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item12f.pdf) [<https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item12f.pdf>]
- g. [Nebulized Bronchodilators](https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item12g.pdf) [<https://www.hhs.texas.gov/sites/default/files/documents/apr-2022-durb-agenda-item12g.pdf>]

13. Review of action items for next meeting: July 22, 2022, 9:00 a.m.

14. Adjournment

The committee may take any action on any agenda item.

Public Comment: HHSC welcomes public comments pertaining to topics related to DURB and Medicaid PDL. Members of the public who would like to provide public comment may choose from the following options:

1. **Oral comments provided virtually:** Members of the public **must** pre-register to provide oral comments virtually during the meeting by completing a Public Comment Registration form at https://texashhsm meetings.org/DURB_PCReg_Apr20_22 [https://texashhsm meetings.org/DURB_PCReg_Apr20_22] and submitting a completed Public Comment Form, [HHS Form 1320](https://www.txvendordrug.com/resources/drug-utilization-review-board/meeting-agendas-and-documents) [<https://www.txvendordrug.com/resources/drug-utilization-review-board/meeting-agendas-and-documents>] no later than 5:00 p.m. Wednesday, April 20, 2022. Please mark the correct box on the Public Comment Registration form and provide your name, either the organization you are representing or that you are speaking as a private citizen and your direct phone number. If you have completed the Public Comment Registration form, you will receive an email the day before the meeting with instructions for providing virtual public comment. Public comment is limited to three minutes. Each speaker providing oral public oral comments virtually must ensure their face is visible and their voice audible to the other participants while they are speaking. Each speaker providing oral public comment must state their name and on whose behalf they are speaking (if anyone). If you pre-register to speak and wish to provide a handout before the meeting, please submit an electronic copy in accessible PDF format with a completed Written Public Comment form, [HHS Form 1334](https://www.txvendordrug.com/resources/drug-utilization-review-board/meeting-agendas-and-documents) [<https://www.txvendordrug.com/resources/drug-utilization-review-board/meeting-agendas-and-documents>], that will be distributed by HHS staff to DURB members and State staff. Handouts are limited to two pages (paper size: 8.5" by 11", one side only). Handouts must be emailed to VDP-Advisory@hhsc.state.tx.us [<mailto:VDP-Advisory@hhsc.state.tx.us>] immediately after pre-registering, but no later than 5:00 p.m. Wednesday, April 13, 2022, and include the name of the person who will be commenting. Do not include health or other confidential information in your comments or handouts. Staff will not read aloud handouts aloud during the meeting, but handouts will be provided to DURB members and State staff.
2. **Written comments:** Members of the public may provide written public comments by completing a Public Comment Registration form, [HHS Form 1334](https://www.txvendordrug.com/resources/drug-utilization-review-board/meeting-agendas-and-documents) [<https://www.txvendordrug.com/resources/drug-utilization-review-board/meeting-agendas-and-documents>] at https://texashhsm meetings.org/DURB_PCReg_Apr20_22 [https://texashhsm meetings.org/DURB_PCReg_Apr20_22]. A member of the public who wishes to provide written public comments must email the comments to VDP-Advisory@hhsc.state.tx.us [<mailto:VDP-Advisory@hhsc.state.tx.us>] no later than 5:00 p.m. Wednesday, April 13, 2022. Please include your name and the organization you are representing or that you are speaking as a private citizen. Written comments must be emailed to HHSC immediately after pre-registering and include the name of the person who will be commenting. Written comments are limited to two pages (paper size: 8.5" by 11", one side only). Do not include health or other confidential information in your comments. Staff will not read written comments aloud during the meeting, but comments will be provided to DURB members and State staff.
3. **Oral comments provided in-person at the meeting location:** Members of the public may provide oral public comment during the meeting in person at the meeting location either by pre-registering using the form above or without pre-registering by completing a form at the entrance to the meeting room. Do not include health or other confidential information in your comments.

Note: These procedures may be revised at the discretion of HHSC.

Contact: Questions regarding agenda items, content, or meeting arrangements should be directed to Maribel O. Castoreno, DUR/PDL Oversight Specialist, Health and Human Services Commission, Medicaid and CHIP Services, 512-552-7672, and VDP-Advisory@hhsc.state.tx.us [<mailto:VDP-Advisory@hhsc.state.tx.us>].
